PT2772249T - Método e composição para tratamento de hipertensão ocular e glaucoma - Google Patents

Método e composição para tratamento de hipertensão ocular e glaucoma

Info

Publication number
PT2772249T
PT2772249T PT140018623T PT14001862T PT2772249T PT 2772249 T PT2772249 T PT 2772249T PT 140018623 T PT140018623 T PT 140018623T PT 14001862 T PT14001862 T PT 14001862T PT 2772249 T PT2772249 T PT 2772249T
Authority
PT
Portugal
Prior art keywords
glaucoma
composition
ocular hypertension
treating ocular
treating
Prior art date
Application number
PT140018623T
Other languages
English (en)
Inventor
Reunamaki Timo
Pellinen Pertti
Oksala Olli
Lehmussaari Kari
Original Assignee
Santen Pharmaceutical Co Ltd
Asahi Glass Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39940592&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT2772249(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Santen Pharmaceutical Co Ltd, Asahi Glass Co Ltd filed Critical Santen Pharmaceutical Co Ltd
Publication of PT2772249T publication Critical patent/PT2772249T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Ophthalmology & Optometry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PT140018623T 2008-05-30 2009-05-28 Método e composição para tratamento de hipertensão ocular e glaucoma PT2772249T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP08397513A EP2127638A1 (en) 2008-05-30 2008-05-30 Method and composition for treating ocular hypertension and glaucoma

Publications (1)

Publication Number Publication Date
PT2772249T true PT2772249T (pt) 2017-08-08

Family

ID=39940592

Family Applications (4)

Application Number Title Priority Date Filing Date
PT140018623T PT2772249T (pt) 2008-05-30 2009-05-28 Método e composição para tratamento de hipertensão ocular e glaucoma
PT97548648T PT2306977E (pt) 2008-05-30 2009-05-28 Método e composição para tratamento de hipertensão ocular e glaucoma
PT201646023T PT3714877T (pt) 2008-05-30 2009-05-28 Método e composição para tratamento de hipertensão ocular e glaucoma
PT170004402T PT3205334T (pt) 2008-05-30 2009-05-28 Método e composição para tratamento de hipertensão ocular e glaucoma

Family Applications After (3)

Application Number Title Priority Date Filing Date
PT97548648T PT2306977E (pt) 2008-05-30 2009-05-28 Método e composição para tratamento de hipertensão ocular e glaucoma
PT201646023T PT3714877T (pt) 2008-05-30 2009-05-28 Método e composição para tratamento de hipertensão ocular e glaucoma
PT170004402T PT3205334T (pt) 2008-05-30 2009-05-28 Método e composição para tratamento de hipertensão ocular e glaucoma

Country Status (27)

Country Link
US (3) US9999593B2 (pt)
EP (7) EP2127638A1 (pt)
JP (9) JP2011521943A (pt)
KR (5) KR102114401B1 (pt)
CN (1) CN102083413B (pt)
AR (2) AR071937A1 (pt)
AU (1) AU2009252210C1 (pt)
BR (1) BRPI0913109B8 (pt)
CA (2) CA2965185A1 (pt)
CY (2) CY1115565T1 (pt)
DK (4) DK2772249T3 (pt)
EA (1) EA023661B1 (pt)
ES (5) ES2808050T3 (pt)
GE (1) GEP20156220B (pt)
HR (4) HRP20220361T1 (pt)
HU (3) HUE058079T2 (pt)
JO (1) JO3039B1 (pt)
LT (3) LT3205334T (pt)
MX (1) MX2010012987A (pt)
MY (1) MY159463A (pt)
PL (4) PL3714877T3 (pt)
PT (4) PT2772249T (pt)
SG (1) SG191628A1 (pt)
SI (4) SI2772249T1 (pt)
TW (1) TWI432202B (pt)
UA (1) UA102257C2 (pt)
WO (1) WO2009145356A1 (pt)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI544927B (zh) 2008-03-17 2016-08-11 愛爾康研究有限公司 具有低濃度的表面活性劑以促進治療劑之生物可利用性的藥學組成物
EP2127638A1 (en) 2008-05-30 2009-12-02 Santen Pharmaceutical Co., Ltd Method and composition for treating ocular hypertension and glaucoma
EP2228058A1 (en) 2009-03-04 2010-09-15 Novagali Pharma S.A. Anionic oil-in-water emulsion containing prostaglandins and uses thereof
EP2389939A1 (en) 2010-05-28 2011-11-30 Novagali Pharma S.A. Use of prostaglandins F2alpha and analogues for the healing of corneal and conjunctival lesions
US20110136872A1 (en) * 2009-12-09 2011-06-09 Burk Robert M Stable aqueous compositions of prostglandin agonist prodrugs and methods for use thereof
JP5681472B2 (ja) * 2009-12-28 2015-03-11 ロート製薬株式会社 眼科用組成物
FR2961694B1 (fr) * 2010-06-29 2013-01-25 Thea Lab Systeme de delivrance polymerique d'une solution non visqueuse a base de prostaglandine sans conservateur
US20130245124A1 (en) * 2010-07-29 2013-09-19 Allergan, Inc. Preservative free bimatoprost solutions
PL2598118T3 (pl) * 2010-07-29 2019-01-31 Allergan, Inc. Roztwory bimatoprost i tymolol bez środków konserwujących
US9061034B2 (en) * 2010-07-29 2015-06-23 Allergan, Inc. Preservative free bimatoprost and timolol solutions
US10272040B2 (en) 2010-08-12 2019-04-30 Nanyang Technological University Liposomal formulation for ocular drug delivery
EP2618810B1 (en) 2010-09-21 2016-11-23 S & V Technologies GmbH Cosmetic composition
EP2452669A1 (en) * 2010-10-29 2012-05-16 Omnivision GmbH Ophthalmic composition
US20120263803A1 (en) * 2011-04-12 2012-10-18 R-Tech Ueno, Ltd. Aqueous ophthalmic composition
CN102716074B (zh) * 2012-06-28 2013-10-16 武汉武药科技有限公司 一种贝美前列素滴眼剂及其制备方法
EP2887923B1 (en) 2012-08-24 2023-04-05 Sun Pharmaceutical Industries Limited Ophthalmic formulation of polyoxyl lipid or polyoxyl fatty acid and treatment of ocular conditions
US9956195B2 (en) 2014-01-07 2018-05-01 Nanyang Technological University Stable liposomal formulations for ocular drug delivery
JP2017502089A (ja) 2014-01-10 2017-01-19 マニスティー パートナーズ エルエルシーＭａｎｉｓｔｅｅ Ｐａｒｔｎｅｒｓ Ｌｌｃ 偏頭痛の処置
CN104766952B (zh) * 2015-04-21 2017-01-25 武汉凯迪工程技术研究总院有限公司 利用生物质气化炉滤渣制备锂离子电池负极材料的方法
ES2747302T3 (es) 2015-06-09 2020-03-10 Medproject Pharma Entw Und Vertriebsgesellschaft Mbh Gel oftálmico de bimatoprost aplicable en gotas
US10105371B2 (en) * 2015-10-09 2018-10-23 Tamara Vrabec Use of medications with neuroprotective properties to prevent or reduce the risk of ischemia-reperfusion injury in a subject
US20180325854A1 (en) * 2015-11-06 2018-11-15 Accuitis Pharmaceuticals, Inc. Use of proteasome inhibitors to treat ocular disorders
US10918694B2 (en) 2016-02-29 2021-02-16 Sun Pharma Global Fze Topical cyclosporine-containing formulations and uses thereof
GR1009040B (el) * 2016-04-19 2017-05-19 Φαρματεν Ανωνυμος Βιομηχανικη Και Εμπορικη Εταιρεια Φαρμακευτικων Ιατρικων Και Καλλυντικων Προϊοντων Φαρμακευτικο οφθαλμικο σκευασμα ελευθερο συντηρητικου
WO2018033854A1 (en) * 2016-08-15 2018-02-22 Santen Pharmaceutical Co., Ltd. Ophthalmic composition and a method for treating ocular hypertension and glaucoma
KR101770324B1 (ko) 2016-11-09 2017-08-22 주식회사태준제약 안압 강하용 점안 조성물
JP2020059652A (ja) * 2016-12-26 2020-04-16 参天製薬株式会社 タフルプロストとクエン酸エステルとを含有するデポ剤
CN110494138B (zh) * 2017-03-27 2023-07-11 兴和株式会社 医药制剂
US20180318319A1 (en) * 2017-05-04 2018-11-08 Ocular Science, Inc. Compositions and Methods for Treating Eyes and Methods of Preparation
JP6931493B2 (ja) 2017-06-22 2021-09-08 ヨンスン ファイン ケミカル カンパニー，リミテッド 緑内障治療用点眼組成物
EP4338751A3 (en) * 2017-12-21 2024-05-22 Santen Pharmaceutical Co., Ltd. Medicament comprising combination of sepetaprost and rho-associated coiled-coil containing protein kinase inhibitor
EP3820445A1 (en) 2018-07-09 2021-05-19 Warszawskie Zaklady Farmaceutyczne Polfa S.A. Ophthalmic dispensing device
CN111632025A (zh) * 2020-03-04 2020-09-08 吉林大学第一医院 一种贝美前列素眼用温度敏感型原位凝胶及其制备方法与应用
CN111840225B (zh) * 2020-08-12 2021-09-14 陈丽娜 一种用于治疗青光眼的滴眼剂及其制备方法
RU2761625C2 (ru) * 2021-02-11 2021-12-13 Общество с ограниченной ответственностью "Гротекс" (ООО "Гротекс") Фармацевтическая композиция тафлупроста
WO2023182480A1 (ja) * 2022-03-25 2023-09-28 株式会社坪田ラボ 水性組成物
WO2023241652A1 (zh) * 2022-06-16 2023-12-21 广州润尔眼科生物科技有限公司 一种药物组合物及其制备方法和应用

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4778815A (en) * 1987-03-18 1988-10-18 Ciba-Geigy Corporation Method of inhibiting cataracts by topical application of a 2-substituted 1,2-benzisoselenazol-3(2H)-one
EP0286903B2 (en) 1987-04-03 2000-03-29 The Trustees Of Columbia University In The City Of New York Use of a prostaglandin in combination with an adrenergic blocking agent for reduction of intraocular pressure
US5409125A (en) 1989-12-11 1995-04-25 Aktiebolaget Astra Unit dose container
DE4027320C2 (de) 1990-08-29 1993-09-30 Ursapharm Arzneimittel Gmbh Fluid-Abgabeeinrichtung für keimfreies Fluid
JPH0655640A (ja) 1992-08-04 1994-03-01 Aavan Internatl:Kk 洗面台カウンター及びその製造方法
JPH06107547A (ja) 1992-10-01 1994-04-19 Aarutetsuku Ueno:Kk 眼科用組成物
AU665287B2 (en) 1992-12-21 1995-12-21 Alcon Laboratories, Inc. Prostaglandin combinations in glaucoma therapy
JP2510066Y2 (ja) 1993-01-20 1996-09-11 東洋製罐株式会社 加熱殺菌可能な液体医薬容器
US5807892A (en) 1994-09-30 1998-09-15 Alcon Laboratories, Inc. Use of certain prostaglandin analogues to treat glaucoma and ocular hypertension
US5631287A (en) 1994-12-22 1997-05-20 Alcon Laboratories, Inc. Storage-stable prostaglandin compositions
AU704938B2 (en) * 1995-11-17 1999-05-06 Alcon Laboratories, Inc. Combination therapy for treating glaucoma
EP0930296B2 (en) 1996-09-17 2005-11-02 Asahi Glass Company Ltd. Fluorinated prostaglandin derivatives and medicines
EP0944530A1 (en) 1996-12-09 1999-09-29 Bausch & Lomb Incorporated Single-use flexible container
JP3480549B2 (ja) 1996-12-26 2003-12-22 参天製薬株式会社 ジフルオロプロスタグランジン誘導体およびその用途
AR002194A1 (es) 1997-03-17 1998-01-07 Sanchez Reynaldo Alemany Instrumento computarizado para el analisis del movimiento.
ES2265166T3 (es) * 1997-10-13 2007-02-01 R-Tech Ueno, Ltd. Composicion para tratamiento de hipertension intraocular o glaucoma.
US6066671A (en) 1997-12-19 2000-05-23 Alcon Laboratories, Inc. Treatment of GLC1A glaucoma with 3-benzoyl-phenylacetic acids, esters, or amides
GB2337740B (en) 1998-05-26 2000-11-15 Spreckelsen Mcgeough Ltd Fluid packaging
ATE285795T1 (de) 1998-07-14 2005-01-15 Alcon Mfg Ltd Polypropylenbasierte behälter für prostaglandin- enthaltende produkte
US6235781B1 (en) 1998-07-14 2001-05-22 Alcon Laboratories, Inc. Prostaglandin product
EP1115406A4 (en) 1998-09-25 2003-03-05 Alcon Lab Inc SUSTAINABLE RELEASE OPHTHALMIC COMPOSITION AND METHOD OF EYE THERAPY
US6096783A (en) 1998-12-15 2000-08-01 Alcon Laboratories, Inc. Cyclobutane prostaglandin analogues as ocular hypotensive agents
AU2183900A (en) 1998-12-24 2000-07-31 Alcon Laboratories, Inc. Ep4 receptor agonists for treatment of dry eye
DK1466889T3 (da) 1999-04-06 2008-09-08 Sepracor Inc O-Desmethylvenlafaxin-succinat
CN1232305C (zh) 2000-06-19 2005-12-21 参天制药株式会社 防腐剂
JP3876355B2 (ja) 2000-09-13 2007-01-31 参天製薬株式会社 点眼液
EP1321144B1 (en) 2000-09-13 2010-12-08 Santen Pharmaceutical Co., Ltd. Eye drops
TW586946B (en) 2000-12-22 2004-05-11 Novartis Ag Process to improve stability
WO2004006826A1 (ja) 2002-07-16 2004-01-22 Senju Pharmaceutical Co., Ltd. 薬液容器及びその製造方法
AU2003261981A1 (en) * 2002-09-09 2004-03-29 Santen Pharmaceutical Co., Ltd. Transparent eye drops containing latanoprost
US7074827B2 (en) 2002-10-24 2006-07-11 Sucampo Ag (Usa) Inc. Method for treating ocular hypertension and glaucoma
ATE450264T1 (de) * 2003-07-31 2009-12-15 Santen Pharmaceutical Co Ltd Prostaglandin enthaltendes produkt
US20050287325A1 (en) 2004-06-25 2005-12-29 Pharmacia & Upjohn Company Pharmaceutical containers with low adsorption/absorption of active ingredients, and a method of testing materials for adsorption/absorption of active ingredients
ATE412400T1 (de) * 2004-11-09 2008-11-15 Novagali Pharma Sa Öl-in-wasser-emulsion mit niedriger konzentration des kationischen mittels und positivem zetapotential
US7562796B2 (en) 2004-11-24 2009-07-21 Holopack International Corp. Dispensing container with flow control system
JP2006187602A (ja) 2004-12-09 2006-07-20 Santen Pharmaceut Co Ltd 分子内にフッ素原子を有するプロスタグランジン含有製品
CN101175496A (zh) * 2004-12-24 2008-05-07 参天制药株式会社 含有前列腺素F2α衍生物的制品
GB0501192D0 (en) * 2005-01-20 2005-03-02 Resolution Chemicals Ltd Stable prostaglandin-containing compositions
ES2393675T3 (es) * 2005-07-13 2012-12-27 Santen Pharmaceutical Co., Ltd. Composición conservante para uso oftálmico
WO2007015510A1 (ja) 2005-08-02 2007-02-08 Santen Pharmaceutical Co., Ltd. 熱的に不安定な薬物の分解抑制方法
CA2625568C (en) 2005-10-10 2013-10-08 Novagali Pharma Sa Ophthalmic emulsions containing prostaglandins
FI126233B (sv) 2006-02-23 2016-08-31 Oy Kwh Mirka Ab Oscillerande slipmaskin
FR2918891B1 (fr) 2007-07-20 2009-09-25 Thea Sa Lab Solution ophtalmique a base de prostaglandines sans conservateur
KR100927617B1 (ko) 2007-11-26 2009-11-23 한국표준과학연구원 열분해 탄소 성분의 나노 크기를 가지는 바이오 센서의감지부를 제작하는 방법
EP2127638A1 (en) 2008-05-30 2009-12-02 Santen Pharmaceutical Co., Ltd Method and composition for treating ocular hypertension and glaucoma

Also Published As

Publication number Publication date
PT3714877T (pt) 2022-03-10
EP2127638A1 (en) 2009-12-02
EP3714877B1 (en) 2022-01-26
KR101988642B1 (ko) 2019-06-12
MY159463A (en) 2017-01-13
CN102083413A (zh) 2011-06-01
JP2011521943A (ja) 2011-07-28
EP2772249B1 (en) 2017-05-03
PL3205334T3 (pl) 2020-11-02
KR20190067272A (ko) 2019-06-14
HRP20200998T1 (hr) 2020-10-16
CY1120351T1 (el) 2019-07-10
JP2018154656A (ja) 2018-10-04
HUE058079T2 (hu) 2022-06-28
JP2017178957A (ja) 2017-10-05
PL3714877T3 (pl) 2022-05-16
JO3039B1 (ar) 2016-09-05
TWI432202B (zh) 2014-04-01
KR102246598B1 (ko) 2021-04-30
EP4035656B1 (en) 2023-11-22
AR071937A1 (es) 2010-07-28
UA102257C2 (uk) 2013-06-25
JP2020073574A (ja) 2020-05-14
AU2009252210A1 (en) 2009-12-03
PL2772249T3 (pl) 2017-10-31
SG191628A1 (en) 2013-07-31
JP2023085558A (ja) 2023-06-20
JP2024079852A (ja) 2024-06-11
JP2014133765A (ja) 2014-07-24
SI2306977T1 (sl) 2014-12-31
SI3205334T1 (sl) 2020-10-30
AU2009252210C1 (en) 2016-04-14
EA023661B1 (ru) 2016-06-30
LT2772249T (lt) 2017-09-11
DK2772249T3 (en) 2017-07-17
JP6649992B2 (ja) 2020-02-19
PT3205334T (pt) 2020-07-31
CY1115565T1 (el) 2017-01-04
BRPI0913109B1 (pt) 2019-10-22
JP7265584B2 (ja) 2023-04-26
EP4035656A1 (en) 2022-08-03
EP3714877A1 (en) 2020-09-30
DK3205334T3 (da) 2020-07-13
KR20160102319A (ko) 2016-08-29
EP2306977B1 (en) 2014-08-13
ES2627837T8 (es) 2018-02-26
DK3714877T3 (da) 2022-02-14
KR102114401B1 (ko) 2020-05-25
US20110152264A1 (en) 2011-06-23
TW201000104A (en) 2010-01-01
LT3714877T (lt) 2022-04-11
WO2009145356A1 (en) 2009-12-03
GEP20156220B (en) 2015-01-26
ES2968837T3 (es) 2024-05-14
JP6148317B2 (ja) 2017-06-14
HUE033103T2 (en) 2017-11-28
SI3714877T1 (sl) 2022-05-31
ES2808050T3 (es) 2021-02-25
HRP20170769T1 (hr) 2017-08-11
HUE049923T2 (hu) 2020-11-30
AR120961A2 (es) 2022-04-06
CN102083413B (zh) 2013-11-06
BRPI0913109A2 (pt) 2017-06-20
JP2016065095A (ja) 2016-04-28
JP2021120412A (ja) 2021-08-19
KR20180008905A (ko) 2018-01-24
KR101650006B1 (ko) 2016-08-22
PL2306977T3 (pl) 2015-01-30
ES2495316T3 (es) 2014-09-17
EP4289446A2 (en) 2023-12-13
EP2306977A1 (en) 2011-04-13
US20210059931A1 (en) 2021-03-04
JP6889789B2 (ja) 2021-06-18
EP3205334B1 (en) 2020-04-29
ES2627837T3 (es) 2017-07-31
CA2724194A1 (en) 2009-12-03
CA2724194C (en) 2017-06-27
US10864159B2 (en) 2020-12-15
KR101820816B1 (ko) 2018-01-22
JP6356868B2 (ja) 2018-07-11
EP3205334A1 (en) 2017-08-16
EP2772249A1 (en) 2014-09-03
HRP20140979T1 (hr) 2014-11-21
ES2907982T3 (es) 2022-04-27
SI2772249T1 (sl) 2017-08-31
HRP20220361T1 (hr) 2022-05-13
AU2009252210B2 (en) 2014-10-16
LT3205334T (lt) 2020-09-25
DK2306977T3 (da) 2014-09-15
EP4289446A3 (en) 2024-01-10
KR20110011707A (ko) 2011-02-08
MX2010012987A (es) 2011-02-24
EA201071413A1 (ru) 2011-06-30
US9999593B2 (en) 2018-06-19
US20180289618A1 (en) 2018-10-11
PT2306977E (pt) 2014-09-22
CA2965185A1 (en) 2009-12-03
BRPI0913109B8 (pt) 2021-05-25
KR20200057801A (ko) 2020-05-26

Similar Documents

Publication Publication Date Title
PT2772249T (pt) Método e composição para tratamento de hipertensão ocular e glaucoma
HK1247821A1 (zh) 用於預防或治療眼科病症的方法和組合物
EP2083862A4 (en) COMPOSITIONS AND METHODS FOR TREATING OCULAR DISEASES AND DISORDERS
LT2374472T (lt) Kompozicijos ir būdai oftalmologinių sutrikimų gydymui
IL186598A0 (en) Composition and method for the treatment or prevention of glaucoma and ocular hypertension
IL202015A0 (en) Methods and compositions for treating skin conditions
IL209948A0 (en) Method of eye treatment for prevention of presbyopia and glaucoma, and means for carrying out said treatment
EP2344155A4 (en) COMPOSITION AND METHOD FOR TREATING A DRY EYE
EP2147975A4 (en) METHOD FOR DETERMINING THE RISK OF APPEARANCE OF GLAUCOMA
IL210097A0 (en) Compositions and methods for treating unfluenza
IL207397A0 (en) Difluorobiphenylamide derivtives for the treatment of ocular hypertension
HK1149545A1 (en) Compositions and methods for treating ophthalmic diseases
EP2120994A4 (en) METHOD AND COMPOSITIONS FOR TREATING HYPOGLYKEMIC CONDITIONS
GB0718918D0 (en) Compositions and methods for treating skin conditions
EP2032130A4 (en) OPHTHALMIC COMPOSITIONS FOR THE TREATMENT OF EYE HIGH PRESSURE
IL209947A0 (en) Compositions and methods for treating corneal inflammation
EP2427052A4 (en) METHODS AND COMPOSITIONS FOR USE IN THE TREATMENT OF OPHTHALMIC DISORDERS
PL2374472T3 (pl) Kompozycje i sposoby leczenia zaburzeń okulistycznych
AU2013207600A1 (en) Methods and apparatus for treating glaucoma
IL197323A0 (en) Novel method and compositions for prevention or treatment of glaucoma and ocular hypertension